Free Trial

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Syndax Pharmaceuticals logo
$9.63 -0.36 (-3.60%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$9.64 +0.00 (+0.05%)
As of 07/25/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Key Stats

Today's Range
$9.55
$10.00
50-Day Range
$8.73
$11.45
52-Week Range
$8.58
$25.07
Volume
1.27 million shs
Average Volume
1.74 million shs
Market Capitalization
$828.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.10
Consensus Rating
Moderate Buy

Company Overview

Syndax Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

SNDX MarketRank™: 

Syndax Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 316th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Syndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Syndax Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syndax Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syndax Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Syndax Pharmaceuticals has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Syndax Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    28.93% of the float of Syndax Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Syndax Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syndax Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    28.93% of the float of Syndax Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Syndax Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Syndax Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    8 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,031.00 in company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.

  • Read more about Syndax Pharmaceuticals' insider trading history.
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More Headlines

SNDX Stock Analysis - Frequently Asked Questions

Syndax Pharmaceuticals' stock was trading at $13.22 at the start of the year. Since then, SNDX shares have decreased by 27.2% and is now trading at $9.63.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings results on Monday, May, 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company's revenue was up 1900.0% on a year-over-year basis.
Read the conference call transcript
.

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' top institutional investors include Aberdeen Group plc (0.35%), Inspire Investing LLC (0.05%) and CWM LLC (0.01%). Insiders that own company stock include Michael A Metzger, Keith A Goldan, Neil Gallagher, Dennis Podlesak, William Meury, Pierre Legault, Briggs Morrison and Peter Ordentlich.
View institutional ownership trends
.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/05/2025
Today
7/27/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNDX
CIK
1395937
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$51.00
Low Price Target
$17.00
Potential Upside/Downside
+254.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$318.76 million
Net Margins
-757.53%
Pretax Margin
-757.52%
Return on Equity
-101.60%
Return on Assets
-58.41%

Debt

Debt-to-Equity Ratio
1.53
Current Ratio
5.80
Quick Ratio
5.75

Sales & Book Value

Annual Sales
$23.68 million
Price / Sales
34.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
2.85

Miscellaneous

Outstanding Shares
86,050,000
Free Float
82,519,000
Market Cap
$828.66 million
Optionable
Optionable
Beta
0.70

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:SNDX) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners